Showing 1 - 12 of 67 reports matching: Metabolic Disorders
Journals
Specialties
Date of Publication
to
Synopsis: 27 randomized controlled trials that examined 9 different active treatments were included in this network meta-analysis to evaluate the efficacy of various treatments compared to placebo plus calcium and vitamin D in the treatment of patients with glucocorticoid-induced osteoporosis. Outcomes assessed in this network meta-analysis were incidence of vertebral fractures, incidence of non-vertebral fractures, and bone mineral density at the lumbar spine and femoral neck. The results of Read More »
Level 2 Meta Analysis
Synopsis: 643 postmenopausal women with osteoporosis who had used oral bisphosphonate for a minimum of 2 years were randomized to either subcutaneous injections of denosumab 60mg - one at baseline and another at 6 months - or intravenous injection of zoledronic acid 5mg. The purpose of this study was to evaluate if denosumab offered noninferior or superior efficacy and safety to zoledronic acid for increasing bone mineral density in this patient population. The increase in Read More »
Level 1 RCT
Synopsis: 94 postmenopausal osteoporotic women were randomized to receive either 60mg denosumab subcutaneously every 6 months, 20ug teriparatide subcutaneously daily, or a combination treatment of both 60mg denosumab and 20ug teriparatide for a duration of 24 months. The purpose of this study was to compare the individual response rates of the three treatment groups in terms of increases in bone mineral density (BMD) at the total hip, femoral neck, lumbar spine, and distal one-third radius shaft. Outcomes were assessed Read More »
Author verified Level 2 RCT
Synopsis: A post hoc analysis was performed combining the data from two previously conducted randomized controlled trials (RCTs) in postmenopausal women (total of 1705 patients) with low adherence to a daily/weekly BP treatment who then transitioned to either denosumab or a monthly BP treatment (ibandronate and risedronate, respectively). This study aimed to compare bone mineral density and bone turnover marker levels. Results indicated that Read More »
Level 2 RCT
Synopsis: Fifteen studies (7 randomized controlled trials, 8 observational studies) were included in this systematic review to determine the efficacy and safety of raloxifene in treatment of postmenopausal Japanese women suffering from osteoporosis or osteopenia. Qualitatively, majority of studies reporting on pertinent outcomes of interest demonstrated significant increase lumbar spine bone mineral density from baseline, low overall vertebral and non-vertebral fracture incidence, and significant changes from baseline in bone-specific alkaline phosphatase and type 1 collagen N-telopeptide levels during treatment with raloxifene. The quality of Read More »
Level 3 Meta Analysis
Synopsis: A total of 27 randomized controlled trials were included in this network meta-analysis investigating the comparative efficacies of bisphosphonates - including alendronate, ibandronate, risedronate, and zoledronic acid - versus placebo or control in patients with low bone mineral density. All studied drugs demonstrated significant effects on vertebral fracture incidence and bone mineral density of the femoral neck; effects sizes of both outcomes were observed to be greatest with zoledronic acid. Ibandronate was the Read More »
Level 2 Meta Analysis
Synopsis: 5 randomized controlled trials investigating the benefits of bisphosphonate therapy in the treatment of femoral head osteonecrosis were included in this meta-analysis. The purpose of this study was to determine whether bisphosphonate treatment should be recommended to patients suffering from this condition. The findings of Read More »
Level 1 Meta Analysis
Synopsis: 436 postmenopausal women with osteoporosis who had been administered oral bisphosphonate therapy for 3 years prior were randomized in a phase 3 clinical trial to subcutaneous romosozumab or subcutaneous teriparatide. The purpose of this study was to compare the change in bone mineral density after 1 year of treatment between the two groups. Reported results demonstrated Read More »
Conference Report
Synopsis: 540 postmenopausal women with normal to low bone mineral density were randomized to 24 months of treatment with either lasofoxifene 0.25mg/day, raloxifene 60mg/day, or daily placebo. The purpose of this study was to compare changes in bone mineral density and bone turnover markers between groups after 24 months of treatment. Change in bone Read More »
Conference Report
Synopsis: A subset of 164 women from the Long-Term Odanacatib Fracture Trial were included in this imaging sub-study to evaluate the effect of odanacatib versus placebo on volumetric bone mineral density (vBMD) of the lumbar spine and total hip. Follow-up was made at 24 months of treatment, and percent change in trabecular vBMD of the lumbar spine and cortical vBMD of total hip were compared. Results demonstrated a Read More »
Conference Report
Synopsis: 643 postmenopausal women with osteoporosis who had been administered oral bisphosphonates for 2 or more years prior to enrollment were randomized to be administered either denosumab or zoledronic acid. The purpose of this study was to compare the change in bone mineral density (BMD) and bone turnover markers after 1 year. Results demonstrated a Read More »
Conference Report
Synopsis: 80 patients with osteoporosis were randomized to receive either alfacalcidol, a vitamin D analogue, or plain vitamin D (cholecalciferol). Both treatment groups also received calcium supplementation and alendronate. The purpose of Read More »
Conference Report